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Background: Vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV) has been rec-
ommended for elderly patients with B cell malignancies and dysfunctions because of their enhanced sus-
ceptibility to pneumococcal infections. More recent recommendations advocate the use of conjugate
pneumococcal vaccines.
Methods: We compared responses to single dose vaccination with either PPV or the 7-valent pneumococ-
cal conjugate vaccine (PCV7) in ﬁfty-six patients P60 years with a diagnosis of multiple myeloma
(n = 24), Waldenstrom’s macroglobulinemia (n = 15) and the non-malignant B cell disorder monoclonal
gammopathy of undetermined signiﬁcance (MGUS) (n = 17), and 20 age-matched controls. Serum was
collected prior to vaccination and 4–8 weeks later, and analyzed for IgG antibody levels to pneumococcal
serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F by ELISA. Functional antibody activity towards pneumococcal
serotypes 4 and 14 was measured using an opsonophagocytic killing assay (OPA).
Results: All patient groups had lower pre-vaccination IgG antibody and OPA titers to the investigated
serotypes compared to the healthy controls. Following vaccination, myeloma patients responded with
signiﬁcant IgG titer increases to 1/7 serotypes and OPA titer increases to 1/2 serotypes. Corresponding
IgG and OPA vaccine responses were 3/7 and 0/2 for Waldenstrom patients, 4/7 and 1/2 for MGUS
patients, and 4/7 and 2/2 for the healthy controls, respectively. Notably high antibody levels without
corresponding OPA titers were seen among a few myeloma patients indicating the presence of non-
functional antibodies. Neither of the two vaccines elicited signiﬁcantly higher serotype-speciﬁc IgG con-
centrations, OPA titers or antibody fold increases in any of the study groups. Hypogammaglobulinemia
and ongoing chemotherapy were associated with poor vaccine responses in a multivariate analysis.
Conclusion: Our ﬁndings conﬁrm that B cell malignancies and disorders among elderly patients are asso-
ciated with suboptimal responses to pneumococcal vaccination. Single-dose PCV7 was not shown to be
superior to PPV.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Multiple myeloma (MM) and Waldenstrom’s macroglobuline-
mia (WM) are hematological malignancies arising from plasma
cells and lymphoplasmacytoid cells, respectively, and mainly afﬂict
aged persons. Monoclonal gammopathy of undetermined signiﬁ-
cance (MGUS) is a related non-malignant disorder engaging B
cells/plasma cells that also affects the elderly and can transform
into malignant disease. Common to these B cell disorders are vary-
ing degrees of hypogammaglobulinemia and clonal overproduction
of non-functional immunoglobulins called M-protein. Besides the
inherent impaired humoral immunity characteristic of B cell
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the disease itself, and further aggravated by chemotherapy and
other immunosuppressive therapies used to treat it.
Multiple myeloma is strongly associated with infectious sus-
ceptibility, which is particularly pronounced during the ﬁrst
months after diagnosis. During this phase, infections with gram-
positive bacteria, above all Streptococcus pneumoniae, predominate,
and are primarily ascribable to diminished immunoglobulin syn-
thesis [1,2]. A British study reported that 45% of early deaths (with-
in 60 days of diagnosis) in MM patients were related to infections,
mainly pneumonia and sepsis [3]. Although less studied, patients
with WM or MGUS also have increased mortality due to pneumo-
nia and sepsis [4,5]. A recent population-based Swedish study
found a more than doubled risk of pneumonia in MGUS patients
compared to matched controls [6].
Pneumococcal vaccination is generally recommended for pa-
tients with B cell malignancies [1,7]. The 23-valent pneumococcal
polysaccharide vaccine (PPV) has been widely used in risk groups
including healthy elderly. A recent meta-analysis estimated the
PPV had a protective efﬁcacy of 74% (95% conﬁdence interval,
55–86%) against invasive pneumococcal disease in adults [8]. How-
ever, its effectiveness in elderly healthy individuals, as well as in
MM patients has been debated [1,2,8,9]. Previous studies of MM
patients have shown suboptimal antibody levels in 50–60% after
vaccination with PPV [10,11]. We have documented that elderly
MM patients have low anti-pneumococcal serum antibody levels
[12].
Conjugated pneumococcal vaccines induce a T cell-dependent,
possibly longer-lasting immune response, and may be more immu-
nogenic than PPV not least in immunocompromised hosts. Regi-
mens involving repeated doses of the 7-valent pneumococcal
conjugated vaccine (PCV7) appear to be promising in hematopoi-
etic stem cell transplant recipients [13–16], and vaccination sched-
ules containing PCV7 followed by PPV have recently been
recommended by the European Group for Blood and Marrow
Transplantation as well as by the Centers for Disease Control and
Prevention [7,17]. Non-transplanted MM patients have been rou-
tinely vaccinated with PPV in our region in the west of Sweden.
To our knowledge, no previous studies on pneumococcal vac-
cine responses in patients with WM or MGUS have been per-
formed. The aims of this study were 1) to investigate the ability
of elderly, non-stem cell transplanted patients with MM, WM or
MGUS to mount an immune response to pneumococcal vaccination
as measured by IgG antibody responses as well as by functional
(opsonophagocytic) antibody activity, and 2) to compare the
immunogenicity of PCV7 to PPV in single dosage in these patient
categories.
2. Materials and methods
2.1 Study population
Patients aged P60 years with MM (n = 24), WM (n = 15) or
MGUS (n = 17) were recruited to the study from the outpatient
clinic of the Dept. of Hematology, Uddevalla Hospital, Sweden, be-
tween May 2008 and March 2009. WHO criteria were used to
establish the hematologic diagnoses [18]. Exclusion criteria were
previous or scheduled hematopoietic stem cell transplantation,
pneumococcal vaccination or infection (septicemia, meningitis or
pneumonia) less than a year prior to the study, and previous severe
adverse reactions (angioedema or anaphylaxia) following any kind
of vaccination. An age-matched control group without hematolog-
ical disorders (n = 20) was recruited during the same period. The
study participants were asked to ﬁll in a questionnaire regarding
previous vaccinations, ongoing medication and smoking habits.Written informed consent was obtained from all patients. The
study was approved by the Regional Ethics Committee in Göteborg.
A total of 81 persons were primarily recruited to the study. Two
individuals, one patient with WM and one control person, with-
drew before the second visit. Three participants were later ex-
cluded due to protocol violations; one control person who was
too young at the time of inclusion, two patients (one MM, one
MGUS) with pneumonia within a year prior to inclusion.
2.2. Vaccination and sampling of study persons
All study persons were given a single intramuscular dose of
pneumococcal vaccine in the upper arm. In each of the four study
groups, subjects were randomized to receive 0.5 ml of either PCV7
(Prevenar; Pﬁzer) or PPV (Pneumo 23; Sanoﬁ Pasteur). The PCV7
vaccine contained 2 lg of the respective polysaccharide of sero-
types 4, 9V, 14, 18C, 19F and 23F, and 4 lg of serotype 6B, all indi-
vidually conjugated to the diphtheria carrier protein CRM197. The
PPV vaccine contained 25 lg of each of the 23 capsular polysaccha-
ride components. Blood samples were collected directly before and
4–8 weeks after vaccination. Serum was separated and stored at
20 C until analyzed. Serious adverse events occurring during
the study and up to three months after its termination were re-
trieved from the patients’ records.
2.3. Laboratory assays
2.3.1. Pneumococcal enzyme-linked immunosorbent assay (ELISA)
Serum IgG antibodies to the seven pneumococcal serotypes (4,
6B, 9V, 14, 18C, 19F, and 23F), present in PCV7 as well as in PPV,
were assayed at Statens Serum Institut, Copenhagen, Denmark,
using an ELISA described in detail elsewhere [19] after cell wall
(CPS, c-polysaccharide) adsorption. A local reference serum cali-
brated to the US standard reference serum 89-SF was used. Anti-
body concentrations were expressed as lg/ml.
2.3.2. Opsonophagocytosis
Functional antibody activity was measured by a modiﬁed two-
fold multiplexed opsonophagocytosis assay (OPA) as previously
described [20,21]. Pneumococcal strains of serotypes 4 and 14
resistant to optochin and streptomycin, respectively, were ob-
tained from BEI Resources (Manassas, VA). Differentiated HL-60
cells (ATCC, Manassas, VA) were used as effector cells to phagocy-
tose pneumococci in the presence of patient serum antibodies and
baby rabbit complement (Invitrogen, Lidingö, Sweden). OPA titers
were expressed as the reciprocal of the serum dilution causing
50% bacterial killing compared with the bacterial growth in the
control wells without serum. The lowest OPA titer that could be
determined was 4. In patients receiving antibiotics during the
study (four MM patients, one WM patient on prophylactic cotrim-
oxazole, one MM patient on cloxacillin), the bactericidal effect of
serum alone was compared to non-antibiotic treated patients,
but no difference was seen. Sera from sixteen patients were ana-
lyzed at the National Institute for Health and Welfare, Helsinki,
Finland. The remaining sera were analyzed at the Dept. of Clinical
Bacteriology, Sahlgrenska University Hospital, Göteborg, Sweden.
2.4. Statistical analyses
Pneumococcal antibody and OPA titers were expressed as geo-
metric means with 95% conﬁdence intervals. Titers below the
detection limit were set to 0.5 times this limit. Comparisons of geo-
metric means before and after vaccination were done using the
Wilcoxon signed rank test, between study groups using the
Mann–Whitney U test. The proportions of subjects with IgG or
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exact test. Graph Pad Prism 5.0 software was used (GraphPad,
San Diego, CA). The multivariate analysis ‘‘Orthogonal partial least
squares projections to latent structures’’ (O-PLS) was used to assess
the inﬂuence of clinical parameters on vaccine responses with the
aid of the SIMCA-P statistical programme (Umetrics, Umeå,
Sweden) [22]. Data derived from the O-PLS models were further
analyzed using the Spearman rank correlation test and the
Mann–Whitney U test as appropriate. P values were two-sided. A
signiﬁcance level of P < 0.05 was used.
3. Results
3.1. Study population
Baseline characteristics of the 76 study persons are presented in
Table 1. The median age did not differ signiﬁcantly between the
study groups. Hypogammaglobulinemia was seen in 92% of MM
patients versus 40% of WM patients (P = 0.0009) and 53% of MGUS
patients (P = 0.008). More than half of the MM patients (63%) had
ongoing chemotherapy and/or immunomodulatory treatment at
the time of vaccination, reﬂecting clinical reality.
3.2. ELISA
Pneumococcal IgG titers before and after vaccination were con-
sistently the lowest in the MM patients. Moreover, a stepwise anti-
body pattern was seen with next-to-lowest titers among WM
patients, followed by MGUS patients, and healthy controls, respec-
tively (Fig. 1, Table 2). Two MM patients differed from the rest: one
had very high pre-immune IgG titers (Fig. 1A and E), the other ap-
peared to respond exceptionally well to vaccination (Fig. 1B and F).
Geometric mean IgG concentrations increased modestly after
vaccination, ranging from no increase to a maximum fourfold
increase (seen for serotype 18C in WM patients who receivedTable 1
Study group characteristics.
Multiple myeloma Waldenstrom
macro-globuli
No. of subjects 24 15
Median age, years (range) 76 (62–88) 75 (62–88)
Female sex, n 12 9
Smokers, n 1 2
Previous pneumococcal vaccination, n 3 3
WBC median, 109 L1 (range)a 4.3 (1.3–9.4) 7.1 (2.6–18)
S-IgG median, g/L (range)b 1.7 (0.1–8.0) 7.5 (1.0–11)
M-protein median, g/L (range)c 27 (0.7–49) 15 (3.0–28)
Hypogammaglobulinemia, s-IgG <6.1, n 22 6
Ongoing immunomodulatory therapy, n 15 1
Treatment regimens, n
Melphalan + prednisone 5 0
Cyclophosphamide + dexamethasone 6 0
Pulse steroids 2 0
Thalidomide 1 0
Bortezomibd 2 0
Fludarabin 0 1
Treatment-naïve subjects, n 3 8
Ongoing antipyretic therapye, n 6 3
Given vaccine type, n
PCV7f 12 8
PPV 12 7
a WBC, white blood cell count; reference level in blood = 3.5–8.8  109 L1.
b S-IgG, serum immunoglobulin G; reference level in serum = 6.1–14.9 g/L.
c M-protein, monoclonal protein.
d One MM patient had a combination regimen of bortezomib, pulse steroids, and mel
e Paracetamol or non-steroid anti-inﬂammatory drugs.
f PCV7, 7-valent pneumococcal conjugate vaccine; PPV, 23-valent pneumococcal polyPCV7) (Table 2). Statistically signiﬁcant IgG increases were seen
for one out of seven serotypes among MM patients (18C), 3/7 ser-
otypes among the WM patients (9V, 18C, 19F), and 4/7 serotypes
among the MGUS patients and controls alike (9V, 14, 18C, 19F).
Baseline IgG antibody concentrations were similar for the PCV7
subgroups and the PPV subgroups for all seven pneumococcal ser-
otypes (Table 2). Following vaccination, no signiﬁcant differences
were seen regarding absolute antibody titers (Table 2) or antibody
fold increases (data not shown) between the vaccine types for any
of the study groups or serotypes. Since the numbers of individuals
in each study group were small, we also calculated combined anti-
body fold increases against all seven serotypes, and found signiﬁ-
cantly higher responses to PCV7 in the WM group (23% higher),
and to PPV in the MGUS group (41% higher) (Table 3), although
all fold increases were 62. For the healthy controls, identical re-
sponse rates were obtained for the two vaccine types (Table 3).
As mentioned, two MM patients displayed very high antibody ti-
ters to all serotypes tested, one patient before, the other after vac-
cination. Both patients were on immunomodulatory treatment and
had low serum IgG levels, and it was suspected that these results
were falsely positive. When these individuals were excluded from
the calculations, combined antibody fold increases were signiﬁ-
cantly higher to PCV7 than to PPV also in the MM group (1.79 vs.
1.60, P = 0.04).
Antibody levels ofP0.5 andP1.0 lg/ml were chosen as points
of reference in accordance with previous studies on immunosup-
pressed patients [16,23,24] since a true correlate of seroprotection
in adults has not been deﬁned. The proportions of subjects with
serotype-speciﬁc (data not shown) or combined (Table 3) IgG anti-
body levels P0.5 and P1.0 lg/ml did not differ between the vac-
cine groups. In total, 63% of the MM patients, 73% of the WM
patients, 88% of the MGUS patients, and 100% of the healthy con-
trols had antibody levels P0.5 lg/ml, and 38% (MM), 60% (WM),
65% (MGUS), and 80% (controls) had IgG P1.0 lg/ml to all seven
serotypes after vaccination.’s
nemia
Monoclonal gammopathy
of undetermined signiﬁcance
Healthy
controls
All groups
17 20 76
71 (60–80) 69 (61–83) 74 (60–88)
11 11 43
2 0 5
3 3 12
5.9 (3.0–8.8) 6.6 (4.2–11.7) -
5.3 (0.3–11) 11 (8.2–19) -
11 (0.5–28) 0 (0–0) -
9 0 37
0 0 16
0 0 5
0 0 6
0 0 2
0 0 1
0 0 2
0 0 1
17 20 48
7 6 22
8 9 37
9 11 39
phalan.
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Fig. 1. Anti-pneumococcal IgG (ELISA) and opsonophagocytic antibody (OPA) titers before and 4–8 weeks after vaccination. (A and B), serotype 4, ELISA; (C and D), serotype 4,
OPA; (E and F), serotype 14, ELISA; (G and H) serotype 14, OPA. (A, C, E, G) show PCV7 vaccinees, (B, D, F, H) show PPV vaccinees. Pre- and post-vaccination titers for each study
person are shown. Note that Y values vary between the serotypes for the ELISA analyses. ⁄P < 0.05; ⁄⁄P < 0.01 (Wilcoxon signed rank test).
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The opsonic assay conﬁrmed the ELISA results regarding sero-
type 14, with the lowest OPA titers occurring in MM patients
followed by WM, MGUS and healthy controls (Fig. 1, Table 4). For
serotype 4, all three patient groups had poorer vaccine responses
than the control group. The high ELISA IgG titers seen in two MM
patients were not conﬁrmed by the OPA results (Fig. 1).
Following vaccination, OPA titers against both pneumococcal
serotypes increased in all study groups, but signiﬁcant rises were
only seen in MM patients who had received PCV7 (serotype 14),
in MGUS patients who had received PPV (serotype 14), and in
healthy controls given either vaccine (serotypes 4 and 14) (Table 4).
Baseline OPA titers did not differ signiﬁcantly between the vac-
cine subgroups (Table 4). No obvious trend favoring either vaccinetype could be discerned in any of the study groups. Hence, statisti-
cally signiﬁcant increments in absolute OPA titers against serotype
14 were seen in MM patients in response to PCV7, in MGUS pa-
tients against serotype 14 after PPV, and to both serotypes follow-
ing vaccination with either of the two vaccines in healthy controls
(Table 4). No statistically signiﬁcant differences were noted regard-
ing the post-vaccination titers evoked by either of the vaccines, in
any of the four study groups (Table 4). The same was true for fold
increases of OPA titers after vaccination (Table 5). Between two-
and ninefold OPA titer increments were noted, with the lowest ele-
vations seen among the MM and WM subgroups (Table 5).
An OPA titer of 8 was chosen as point of reference in accordance
with previous studies [25,26]. The proportions of patients with
OPA titersP8 were similar between the vaccine subgroups (Table
5). In total, 8% of the MM patients, 27% of the WM patients, 29% of
Table 2
Anti-pneumococcal IgG antibodies among PCV7 and PPV vaccinees, respectively, before and after vaccination.
Vaccine, study
group
Timepoint Geometric mean IgG concentration, lg/ml (95% conﬁdence interval), by serotype
4 6B 9V 14 18C 19F 23F
PCV7
MM T0 0.44 (0.18–1.09) 3.58 (1.37–9.41) 0.66 (0.22–2.00) 2.40 (0.90–6.43) 0.52 (0.25–1.07) 1.82 (0.70–4.71) 1.13 (0.41–3.09)
T1 0.61 (0.26–1.39) 3.79 (1.85–7.77) 0.72 (0.27–1.95) 2.49 (1.05–5.95) 0.98 (0.53–1.81) 2.72 (1.25–5.93) 1.49 (0.75–2.91)
WM T0 0.77 (0.43–1.38) 4.47 (2.99–6.68) 1.18 (0.70–1.97) 3.99 (2.78–5.74) 0.82 (0.49–1.37) 2.76 (1.68–4.54) 1.99 (1.34–2.97)
T1 1.12 (0.54–2.32) 5.69 (2.95–10.96) 2.10 (0.81–5.46)⁄⁄ 2.82 (0.87–9.10) 3.31 (0.86–
12.34)⁄
5.89 (1.92–18.11)⁄⁄ 2.98 (1.56–5.70)
MGUS T0 1.34 (0.45–3.95) 11.56 (5.29–
25.26)
3.07 (1.29–7.24) 7.75 (4.12–14.60) 1.91 (0.81–4.49) 5.04 (1.99–12.79) 4.04 (1.67–9.79)
T1 2.13 (0.78–5.84) 11.75 (5.51–
25.07)
5.04 (1.64–
15.54)⁄⁄
8.09 (4.37–15.00) 3.11 (1.19–8.13)⁄⁄ 5.31 (2.10–13.41) 5.24 (1.57–
17.51)
Controls T0 1.68 (1.08–2.63) 8.27 (4.77–14.34) 3.32 (1.85–5.98) 10.22 (7.38–14.14) 2.21 (1.41–3.46) 7.12 (4.28–11.83) 3.69 (2.78–4.90)
T1 2.66 (1.10–6.48) 8.28 (4.12–16.66) 7.77 (2.99–
20.18)⁄
16.71 (8.24–
33.90)⁄
8.18 (2.87–
23.34)⁄⁄
10.01 (4.65–21.57) 7.37 (2.74–
19.78)
PPV
MM T0 0.31 (0.13–0.74) 2.55 (0.96–6.80) 0.66 (0.24–1.79) 1.86 (0.75–4.64) 0.49 (0.25–0.97) 1.36 (0.60–3.08) 0.83 (0.36–1.90)
T1 0.65 (0.19–2.23) 4.23 (1.29–13.86) 1.36 (0.36–5.09) 4.67 (1.40–15.65) 1.15 (0.36–3.64)⁄ 2.25 (0.67–7.58) 1.69 (0.46–6.23)
WM T0 1.06 (0.61–1.83) 6.22 (3.25–11.91) 1.74 (1.03–2.95) 5.39 (3.07–9.47) 1.14 (0.52–2.47) 3.62 (2.18–6.02) 2.59 (1.68–3.98)
T1 1.39 (0.76–2.55) 6.94 (4.26–11 28) 2.19 (1.18–4.07) 9.02 (2.85–28.52) 1.67 (0.60–4.63) 4.64 (2.48–8.71) 3.19 (2.14–4.76)
MGUS T0 1.16 (0.56–2.41) 7.21 (3.07–16.91) 1.86 (0.85–4.07) 9.32 (5.40–16.08) 2.59 (1.83–3.65) 4.60 (2.71–7 .80) 3.24 (1.69–6.24)
T1 1.56 (0.67–3.66) 8.24 (3.71–18.27) 4.02 (1.40–
11.57)⁄
15.67 (7.58–
32.34)⁄⁄
7.45 (4.18–
13.27)⁄
9.65 (4.91–18.98)⁄ 6.55 (3.08–
13.93)
Controls T0 1.58 (0.75–3.30) 11.24 (6.74–
18.73)
3.71 (2.09–6.58) 9.04 (4.90–16.69) 3.07 (1.51–6.21) 8.84 (5.34–14.63) 4.16 (2.61–6.65)
T1 2.71 (1.54–4.78) 13.83 (9.31–
20.52)
7.98 (3.83–
16.62)⁄⁄
18.81 (9.60–
36.86)⁄
8.30 (4.08–
16.86)⁄⁄
14.86 (8.04–
27.46)⁄⁄
5.70 (3.57–9.10)
PCV7, 7-valent pneumococcal conjugate vaccine; PPV, 23-valent pneumococcal polysaccharide vaccine.
MM, multiple myeloma; WM, Waldenstrom’s macroglobulinemia; MGUS, monoclonal gammopathy of unknown signiﬁcance.
T0, baseline (i. e., before vaccination); T1, 4–8 weeks after vaccination.
⁄P < 0.05; ⁄⁄P < 0.01. Comparison of post vs. pre-vaccination antibody concentrations for each study group, respectively; Wilcoxon signed rank test.
P values for comparisons of vaccine subgroups (PCV7 vs. PPV; pre and post vaccination) are all >0.05 (Mann–Whitney U test).
Table 3
Number of subjects with anti-pneumococcal IgG titers P0.5 and P1.0 lg/ml to all seven investigated serotypes before and after vaccination with either PCV7 or PPV, and
geometric means of antibody fold increases combined for all seven serotypes.
Study group Time-point IgG P0.5 lg/ml (%) IgG P1.0 lg/ml (%) IgG fold titer increase
PCV7 PPV PCV7 PPV PCV7 PPV P
MM T0 4 (33) 5 (42) 2 (17) 2 (17)
T1 7 (58) 8 (67) 2 (25) 6 (50) 1.29 2.03 0.97
WM T0 6 (75) 6 (86) 2 (25) 2 (29)
T1 5 (63) 6 (86) 5 (63) 4 (57) 1.62 1.32 0.01
MGUS T0 5 (63) 7 (78) 4 (50) 5 (56)
T1 8 (100) 7 (78) 5 (63) 6 (67) 1.30 1.83 0.03
Controls T0 9 (100) 10 (91) 6 (67) 7 (64)
T1 9 (100) 11 (100) 6 (67) 10 (91) 1.81 1.79 0.45
PCV7, 7-valent pneumococcal conjugate vaccine; PPV, 23-valent pneumococcal polysaccharide vaccine.
MM, multiple myeloma; WM, Waldenstrom’s macroglobulinemia; MGUS, monoclonal gammopathy of unknown signiﬁcance.
T0, baseline (i. e., before vaccination); T1, 4–8 weeks after vaccination.
Numbers in parentheses indicate percent responders.
P values for comparisons of vaccine subgroups (PCV7 vs. PPV) regarding antibody titers P0.5 and P1.0 lg/ml are all >0.05 (Fisher’s exact test).
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P8 to both serotypes after vaccination.
3.4. Association of clinical variables with vaccine response
Data were analyzed by the multivariate technique of O-PLS to
construct a model showing the relationship between response to
vaccination as measured by post-vaccination OPA titers to serotype
14 and patient characteristics. The model had an explanatory
power of 50% (r2 = 0.50) and validity of 16% (q2 = 0.16). According
to the model, variables associated with good vaccine responses
were high levels of serum IgG and WBC, and no previous chemo-
therapy. Corresponding univariate correlation analyses were
signiﬁcant only for IgG and WBC in the WM group (data notshown). Conversely, hypogammaglobulinemia, high levels of
M-protein and ongoing therapy with cyclophosphamide and dexa-
methasone, or other immunomodulators were negatively associ-
ated with vaccine responses in the O-PLS model. This tendency
was seen in univariate, group-speciﬁc analyses as well but did
not reach statistical signiﬁcance (data not shown). None of the nine
MM andWM patients with serum IgG levels <1.0 g/L had a clear re-
sponse to vaccination, i.e., OPA titers >8 to both serotype 4 and 14,
compared to six of the remaining 30 patients. This difference did
not quite reach statistical signiﬁcance. No association was found
between post-vaccination OPA titers and age, sex, smoking habits,
previous pneumococcal vaccination, given vaccine type, ongoing
antipyretic therapy, or interval (days) between vaccination and
the follow-up serum sampling.
Table 4
Anti-pneumococcal functional antibody titers as measured by opsonophagocytic assay (OPA) among PCV7 and PPV vaccinees, respectively, before and after vaccination.
Vaccine, study group Timepoint Geometric mean OPA titer (95% conﬁdence
interval), by serotype
Vaccine, study group Timepoint Geometric mean OPA titer (95% conﬁdence
interval), by serotype
4 14 4 14
PCV7 PPV
MM T0 2.00 (2.00–2.00) 2.00 (2.00–2.00) MM T0 2.00 (2.00–2.00) 2.51 (1.52–4.13)
T1 5.21 (1.45–18.69) 5.76 (2.58–12.88)⁄ T1 4.50 (1.52–13.29) 7.68 (1.91–30.82)
WM T0 2.00 (2.00–2.00) 3.08 (1.51–6.27) WM T0 2.00 (2.00–2.00) 2.66 (1.33–5.31)
T1 4.53 (1.23–16.73) 16.34 (1.45–184.2) T1 4.30 (1.27–14.55) 10.57 (0.73–152.6)
MGUS T0 2.00 (2.00–2.00) 2.00 (2.00–2.00) MGUS T0 2.00 (2.00–2.00) 4.52 (1.19–17.22)
T1 11.27 (1.13–112.3) 7.25 (1.51–34.81) T1 4.81 (1.73–13.39) 34.30 (5.72–205.7)⁄
Controls T0 5.74 (1.13–29.2) 24.47 (3.29–181.9) Controls T0 3.43 (1.46–8.05) 11.54 (1.83–72.70)
T1 37.69 (3.60–294.5)⁄ 119.9 (11.4–1260)⁄ T1 31.33 (5.50–178.6)⁄ 107.5 (19.16–602.6)⁄
PCV7, 7-valent pneumococcal conjugate vaccine; PPV, 23-valent pneumococcal polysaccharide vaccine.
MM, multiple myeloma; WM, Waldenstrom’s macroglobulinemia; MGUS, monoclonal gammopathy of unknown signiﬁcance.
T0, baseline (i. e., before vaccination); T1, 4–8 weeks after vaccination.
⁄P < 0.05. Comparison of post vs. pre-vaccination antibody concentrations for each study group, respectively; Wilcoxon signed rank test.
P values for comparisons of vaccine subgroups (PCV7 vs. PPV; pre and post vaccination) are all >0.05 (Mann–Whitney U test).
Table 5
Number of subjects with opsonophagocytic (OPA) titers P8 to pneumococcal serotypes 4 and 14, respectively, before and after vaccination with either PCV7 or PPV, and
geometric means of OPA titer fold increases.
Study group Time-point Serotype 4 Serotype 14
OPA titer P8 (%) OPA fold titer increase OPA titer P8 (%) OPA fold titer increase
PCV7 PPV PCV7 PPV PCV7 PPV PCV7 PPV
MM T0 0 (0) 0 (0) 0 (0) 1 (8)
T1 3 (25) 2 (17) 2.61 2.25 4 (33) 4 (33) 2.88 3.06
WM T0 0 (0) 0 (0) 1 (13) 1 (14)
T1 2 (25) 2 (29) 2.27 2.15 4 (50) 3 (43) 5.31 3.98
MGUS T0 0 (0) 0 (0) 0 (0) 2 (22)
T1 3 (38) 3 (33) 5.64 2.41 3 (38) 7 (78) 3.63 7.58
Controls T0 2 (22) 2 (18) 5 (56) 4 (36)
T1 5 (56) 6 (55) 6.56 9.14 7 (78) 9 (82) 4.93 9.32
PCV7, 7-valent pneumococcal conjugate vaccine; PPV, 23-valent pneumococcal polysaccharide vaccine.
MM, multiple myeloma; WM, Waldenstrom’s macroglobulinemia; MGUS, monoclonal gammopathy of unknown signiﬁcance.
T0, baseline (i. e., before vaccination); T1, 4–8 weeks after vaccination.
Numbers in parentheses indicate percent responders.
P values for comparisons of vaccine subgroups (PCV7 vs. PPV) regarding OPA titersP8 lg/ml or OPA fold titer increases are all >0.05 (Fisher’s exact test and Mann–Whitney U
test, respectively).
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Five unforeseen episodes of hospitalization in four patients
were recorded during the follow-up period. TwoMM patients were
diagnosed with fever of unknown origin. A third MM patient vac-
cinated with PPV developed pleuritis and multiorgan failure two
months after study inclusion, and died. The fourth MM patient suc-
cumbed to pneumococcal septicemia two weeks after PCV7 vacci-
nation; the pneumococcal strain was not serotyped and the patient
lacked a measurable vaccine response. The ﬁfth case was an MGUS
patient who was hospitalized because of myocardial infarction two
weeks after vaccination with PPV.4. Discussion
A recurring problem when comparing studies of pneumococcal
vaccine responses is the lack of a consensus deﬁnition of immune
protection in adults. The World Health Organization has proposed
a titer of 0.35 lg/ml as a cut-off level for protection against inva-
sive pneumococcal disease in infants [27]. Although adults gener-
ally have higher antibody levels than infants, cut-off IgG titers
between 0.15 and 1.0 lg/ml have been used in adult vaccination
studies, as well as antibody fold increases [14,24,28]. We chose
two cut-off levels, 0.5 and 1.0 lg/ml, to allow for comparisons with
previous vaccination studies of adult patients with otherhematological malignancies [14,16,23]. The higher cut-off level
may be more adequate in our case since an ELISA method without
serotype 22F pre-adsorption was used.
As expected, considering their relatively more profound im-
mune dysfunction, the lowest pneumococcal IgG concentrations
were found among the MM patients. After vaccination, antibody
levels P1.0 lg/ml to all seven serotypes were seen in 38% of the
patients, and a statistically signiﬁcant increase in IgG titers was
noted only for one of the seven investigated serotypes. These ﬁnd-
ings are consistent with previous studies describing low baseline
antibody titers and poor pneumococcal vaccine responses among
patients with myeloma [10,11]. Low post-immunization antibody
levels have further been associated with an increased risk of septi-
cemic episodes in MM patients [10]. Two thirds of our MM patients
were on chemotherapy or immunomodulatory medication at the
time of the study, and treatment-induced immunosuppression
should partly account for the poor vaccine responses in this group.
However, we could not demonstrate a statistically signiﬁcant asso-
ciation between ongoing chemotherapy and OPA titers after vacci-
nation, perhaps because of small patient series. The tendency
towards weaker vaccine responses was seen particularly in pa-
tients on cyclophosphamide and dexamethasone treatment, a de-
ﬁned risk group for infectious complications [1].
The WM and the MGUS patients displayed lower baseline anti-
pneumococcal antibody levels compared to the healthy controls,
indicating an increased susceptibility to pneumococcal infection
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stepwise pattern was seen with the lowest antibody titers among
MM patients, followed by WM patients, MGUS patients, and
healthy controls, respectively. As expected, post-vaccination titers
were lower than among the control persons, and 60% of WM
patients, 65% of MGUS patients compared to 80% of healthy con-
trols developed IgG antibody levelsP1.0 lg/ml to all seven inves-
tigated serotypes. MGUS patients are a heterogeneous group. Our
patient cohort had a high rate of hypogammaglobulinemia (53%)
and high levels of M-protein (median 11 g/L), and had inferior vac-
cine responses to the healthy controls. Our ﬁndings together with
recent studies showing increased mortality and morbidity from
pneumonia and sepsis among MGUS patients [5,6] suggest MGUS
patients should be monitored more closely regarding infectious
complications.
The tendency towards lower post-vaccination pneumococcal
antibody activity in patients with high M-protein levels and hypo-
gammaglobulinemia compared to those with normal levels of
polyclonal serum IgG was expected. Hypogammaglobulinemia
has previously been associated with poor vaccine responses among
patients with hematological malignancies [1,10,14]. In contrast to
other studies [10,14,28] we did not ﬁnd a relation between age
or sex and vaccine response.
The gold standard for evaluation of humoral immunity to pneu-
mococci is measurement of the functionality of the pneumococcal
antibodies using a killing-type opsonophagocytosis assay. This is
even more essential since the functionality of pneumococcal IgG
antibodies seem to wane in the elderly [29,30], which correlates
with higher incidence of pneumococcal disease [31]. We selected
to measure OPA titers to a poorly immunogenic pneumococcal
serotype (4), and a highly immunogenic one (14), both of which
are important agents of pneumococcal disease among elderly per-
sons in Sweden [32]. The OPA analyses conﬁrmed the lower IgG
antibody titers seen among the patient groups, particularly in
MM, both before and after vaccination. The proportions of patients
with OPA titers above the chosen reference level of 8, which has
been suggested as an equivalent of an IgG level of 0.35 lg/ml, were
low; 8% of the MM patients, 27% of the WM patients, 29% of the
MGUS patients, and 55% of the healthy controls had OPA titers
P8 to both serotypes after vaccination.
Importantly, the very high IgG antibody titers seen in a few MM
patients could not be conﬁrmed by the OPA analyses, thus suggest-
ing the presence of cross-reactive, dysfunctional antibodies. Dis-
crepancies between ELISA and OPA results have previously been
described in elderly populations [29,30]. Simell et al. showed that
signiﬁcantly higher pneumococcal antibody concentrations were
required to achieve the same killing capacity of pneumococci in
adults P65 years compared to those <65 years. In contrast, a re-
cent study on allogeneic hematopoietic stem cell transplant pa-
tients showed good correlation of post-vaccination ELISA and
OPA titers after pneumococcal vaccination [33]. However, these re-
sults might not be comparable to ours since the patients had other
hematological conditions and were younger (median age 37 years)
than in our study.
Conjugate vaccines, in contrast to polysaccharide vaccines, elicit
T cell-dependent immune responses and are capable of inducing
immunologic memory. It could be anticipated that patients with
defective B cells due to malignancies or other B cell disorders
would respond better to a T cell-dependent vaccine. However, this
study could not conﬁrm the superiority of single-dose vaccination
with PCV7 over PPV. Kumar et al. reported slightly better immune
responses (deﬁned as a Ptwofold antibody titer increase and an
absolute titer of P0.35 lg/ml) in allogeneic hematopoietic stem
cell transplant recipients who had received PCV7 six months after
transplantation compared to those who received PPV [34]. The ci-
ted vaccination regimen was preceded by vaccination of thehealthy stem cell donors with the same vaccine types before trans-
plantation, which makes comparisons difﬁcult. In a study of HIV-
infected adults, patients were randomized to receive either PCV7
followed by PPV one month later, or a single dose of PPV. Signiﬁ-
cantly better antibody responses (deﬁned as a Ptwofold antibody
titer increase and an absolute titer ofP1.0 lg/ml) were seen in the
prime-boosted study group [24]. Since single dosage was used in
our study, it is difﬁcult to draw conclusions regarding the putative
efﬁcacy of repeated doses with either of the vaccine types. How-
ever, the goal of this study was to evaluate whether a single dose
of the conjugate vaccine would be clearly superior to the polysac-
charide vaccine, which our results did not support.
The main limitation of this study was the small series of pa-
tients. The strengths were that we studied ‘‘under-investigated’’
patient groups, who in addition to high age with concomitant
immunosenescence have profoundly depressed humoral immu-
nity. Hence, not only MM patients, but also WM and MGUS pa-
tients should be considered as high risk groups for pneumococcal
disease. There is little evidence to formulate recommendations
for pneumococcal vaccination in these patients to ensure as good
protection as possible. A strategy combining conjugate and poly-
saccharide vaccines is an attractive alternative to enhance vaccine
responses and broaden serotype coverage. However, it is of high
priority to elucidate the immune mechanisms that underlie the
poor vaccine responses to the two conceptually different vaccines
to understand how to help these patients the most. A recent study
showed that the polysaccharide vaccine gave rise to lower frequen-
cies of pneumococcus-speciﬁc switched memory B cells in older
adults [35]. Whether this also holds true for immunosuppressed
patients with hematological malignancies is presently unknown.
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